Form 4: Axogen Director Receives Equity Grant

Axogen, Inc. Director Thomas Paul was granted 5,579 restricted stock units valued at $235,000 as an annual equity award.

Summary

• Thomas Paul, a Director at Axogen, Inc., received an annual equity grant on June 24, 2026.
• The grant consists of 5,579 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Axogen, Inc. common stock.
• The total valuation of the equity grant was $235,000 as of the grant date.
• These RSUs are scheduled to vest on June 24, 2027, marking the one-year anniversary of the grant date.
• This grant is in recognition of services rendered as a Director on the Axogen, Inc. Board of Directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation practice for a company director and does not contain new financial performance data or strategic shifts.

Positives

• Director compensation through equity grants aligns incentives with long-term shareholder value.
• The grant of 5,579 RSUs valued at $235,000 indicates continued investment in key leadership.
• Vesting over one year encourages continued service and commitment to the company's performance.

Future Outlook

The restricted stock units granted to Director Thomas Paul are set to vest on June 24, 2027, indicating a one-year commitment period.

Industry Context

StockSavvy.ai notes that equity grants to directors are a common practice in the biotechnology and medical device sectors, such as Axogen, Inc., to attract and retain experienced leadership and align their interests with those of shareholders.

Stakeholder Impact

• Shareholders: The equity grant aligns director compensation with company performance, potentially benefiting shareholders through motivated leadership.
• Employees: This filing does not directly impact employees but reflects standard compensation practices for the board.
• Management: The grant reinforces the company's commitment to its board members.

Next Steps

• Director Thomas Paul will hold the restricted stock units until their vesting date on June 24, 2027.
• Upon vesting, the RSUs will convert into 5,579 shares of Axogen, Inc. common stock.

Key Dates

Keywords

Axogen Inc, AXGN, Form 4, SEC Filing, Director Compensation, Equity Grant, Restricted Stock Units, Thomas Paul, Insider Transaction